北京若生智能科技有限公司
Drug Database
CO

COVID-19 vaccine (Abdala / CIGB 66 / CIGB66)

✓ Approved

CIGB · 疫苗 · 疫苗

什么是 COVID-19 vaccine？

COVID-19 vaccine 是一种疫苗，由CIGB研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Abdala, CIGB 66, CIGB66
公司CIGB
药物类别疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, CIGB

治疗适应症

COVID-19 vaccine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsCOVID-19✓ Approved

相关研究文献

PubMedEpidemiology and infection2026-10-26

An investigation into post-pandemic ethnic group and deprivation inequalities in influenza and COVID-19 hospitalizations.

Scott Meg M, Browning Lucy L, Roberts Tirion T, De Boer Jessica J et al.

Health system decision-makers need evidence on how modifiable factors contribute to inequalities to inform effective interventions. We examined ethnic group and deprivation inequalities in influenza and COVID-19 hospitalizations in England (2023-2024) among vaccine-eligible individuals, using causal mediation analysis to assess the roles of deprivation, vaccination uptake and comorbidities. For influenza, hospitalization odds were highest among Pakistani and Bangladeshi groups, compared with White British individuals. Deprivation mediated 26% of the total ethnic group effect for the Pakistani group and 41% for the Bangladeshi group, whilst comorbidities contributed little. Ethnic group differences in COVID-19 hospitalizations were minimal in this post-pandemic period. For both infections, the most deprived group had disproportionately high hospitalization compared to the least deprived. For influenza, vaccination uptake mediated 17%-26% of deprivation effects, whilst for COVID-19, there were no meaningful residual deprivation inequalities after including vaccination uptake and comorbidities. Vaccination uptake and deprivation mediate a substantial proportion of inequalities in hospitalization for influenza and COVID-19 in the vaccine-eligible cohort. Improving vaccination coverage in under-vaccinated groups should remain a public health priority.

PMID 42929057
阅读全文 →
PubMedAdvances in therapy2026-10-26

Evaluation of Potential Prognostic Biomarkers for Identifying Adults Hospitalised with COVID-19 at Increased Risk of Adverse Clinical Outcomes.

Hu Xuguang X, Setiadi A Francesca AF, Detalle Laurent L, Sexton Dan D et al.

Elevated levels of circulating cytokines and immune cells are often observed in patients with coronavirus disease 2019 (COVID-19), some of which have been associated with disease severity and clinical outcomes across various medical interventions. We evaluated 50 biomarkers and immune cell types in blood from patients in a randomised controlled trial and hypothesised that baseline inflammatory cytokines and haematologic markers would be associated with COVID-19 severity and outcomes, and a composite biomarker score derived through statistical and machine learning capturing complementary immune pathways could provide stronger prognostic value than individual biomarkers. COMMUNITY was a phase 3, randomised, adaptive-platform study in adult patients hospitalised with COVID-19 with clinical severity grade 2-5 (8-point ordinal scale), enrolled November 24, 2020, to June 4, 2021. An exploratory biomarker analysis used clinical laboratory assessments and serum cytokine data collected from baseline up to day 29 (or discharge) from patients randomised to placebo or apremilast + standard of care (baseline only). Healthy volunteers and ambulatory patients with COVID-19 (not part of the study) were evaluated for comparison. Interleukin (IL)-6, IL-8, IL-10, and tumour necrosis factor alpha (TNFα) were higher at baseline in 378 hospitalised patients than healthy volunteers or ambulatory patients. These cytokines and several haematological markers (including neutrophil count and percentage) showed positive associations with clinical severity and were inversely associated with clinical outcomes. A composite score was derived from baseline IL-6 levels and percentage of neutrophils and showed a strong association with patient overall survival. With a tertile cutoff at which composite scores ≤ 72.1 indicate high-risk patients, the estimated hazard ratio of mortality from COVID-19 infection was 14.3 (95% confidence interval 4.1, 49.3; P < 0.0001). This novel composite score was strongly associated with overall survival in adults hospitalised with COVID-19 and showed improved performance over its individual components. EudraCT 2020-002594-10; ClinicalTrials.gov identifier, NCT04590586 ( https://clinicaltrials.gov/study/NCT04590586 ).

PMID 42928084
阅读全文 →
PubMedBMC public health2026-10-26

Non-communicable diseases and COVID-19 outcomes: insights from the 2021 Iran STEPS survey.

Haghdoost Bahar B, Riazi-Isfahani Sahand S, Abdi Zhaleh Z, Harirchi Iraj I et al.

The association between non-communicable diseases (NCDs) and COVID-19 has imposed a significant burden on health systems, particularly in middle-income countries. This study aimed to evaluate the association between major NCDs, socioeconomic determinants, and COVID-19 outcomes (infection, hospitalization, and ICU admission) using nationally representative data from Iran. This secondary analysis utilized data from the 2021 National STEPS Survey, a cross-sectional study comprising 27,874 adults aged ≥ 18 years across all 31 provinces of Iran. The study followed the World Health Organization stepwise approach. COVID-19 history and outcomes were assessed via a dedicated module. Multivariable logistic regression models were employed to estimate Odds Ratios (OR) and 95% Confidence Intervals (CI), adjusted for demographic and socioeconomic confounders. The analytic sample comprised 27,874 adults, of whom approximately 70% were aged 25-59 years. In multivariable analyses, COVID-19 infection was significantly associated with urban residence (OR = 1.98, 95% CI:1.74-2.26) and the wealthiest socioeconomic status (OR = 1.58, 95% CI:1.34-1.84), whereas current smoking showed an inverse association (OR = 0.83, 95% CI:0.73-0.96). Regarding healthcare utilization, using outpatient service was only associated with supplementary health insurance (OR = 1.28, 95% CI:1.04-1.57). Diabetes (OR = 1.83, 95% CI:1.33-2.54), abnormal Body Mass Index (BMI) (OR = 1.48, 95% CI:1.06-2.07), and age over 60 years (OR = 6.46, 95% CI:2.51-16.63) were associated with higher odds of hospitalization, whereas smoking (OR = 0.60, 95% CI:0.39-0.93) and the highest socioeconomic status (OR = 0.61, 95% CI:0.39-0.96) were associated with lower odds. Hypertension showed no significant association with the risk of infection (p = 0.893) or hospitalization (p = 0.215). Due to the limited number of events and lack of statistical significance in the univariate analysis, Intensive care unit (ICU) admission was not included in the multivariable model. This study underscores the significant role of specific NCDs as independent predictors of COVID-19 infection and disease severity. Socioeconomic and demographic factors, including older age, urban residency, higher wealth status, and insurance coverage, were key determinants of both infection rates and healthcare utilization. The observed association between tobacco use and COVID-19 outcomes requires cautious interpretation. These findings highlight the necessity of integrating NCD management into pandemic preparedness and ensuring equitable access to healthcare and insurance to mitigate health disparities and enhance population resilience.

PMID 42928200
阅读全文 →
PubMedJournal of medical virology2026-10-26

Early Risk Stratification of COVID-19 Associated Cytokine Storm Using a Four-Cytokine Cumulative Score: A Retrospective Cohort Study.

Yin Junyu J, Huang Xianxu X, Ou Xin X, Xu Shilin S et al.

Cytokine storm (CS) is a major immunopathological driver of severe illness and death in COVID-19, yet practical tools for its early identification remain limited. This study aimed to identify early predictive biomarkers, characterize their lead times and develop a cumulative cytokine score for early risk stratification of COVID-19-associated CS. In this single-center retrospective cohort study, 295 hospitalized patients with COVID-19 were included. Admission cytokines and inflammatory markers were analyzed. Cox proportional hazards models were used to identify predictors of CS and in-hospital mortality. Receiver operating characteristic analysis was performed to determine optimal cut-offs, and the interval between biomarker elevation above the cut-off and CS onset was defined as the early warning interval. A four-cytokine cumulative score (0-4 points; IL-6, IL-8, IL-10, TNF-α) was constructed. Internal validation was performed using 2,000 bootstrap resamples. Cytokines increased approximately 4-5 days prior to CS onset, earlier than CRP and d-dimer. In the multivariable model integrating clinical variables, a cumulative cytokine score of 3-4 was independently associated with increased CS risk (HR = 4.078, 95% CI: 1.180-14.101, p = 0.026) and higher in-hospital mortality (HR = 22.026, 95% CI: 2.569-188.846, p = 0.005). The score demonstrated good discriminative performance for CS prediction (AUC = 0.795). A cumulative cytokine score integrating multiple inflammatory pathways may offer a theoretical basis for the early auxiliary diagnosis and risk stratification of COVID-19-associated CS.

PMID 42929754
阅读全文 →
PubMedThe Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques2026-10-26

Reviewer Comment on Gros et al.: "Virtual Care Trends in Older Adults with Parkinson's Disease in Urban and Rural Ontario, Canada During COVID-19".

Stamenova Vess V

PMID 42928470
阅读全文 →
PubMedBMC health services research2026-10-26

Workplace and personal predictors of well-being in the broader maternity and neonatal workforce during COVID-19: evidence from a multicentre survey.

Lindgren Alexander J AJ, Callaway Leonie L, Burke Kylie K, Ryan Elizabeth E et al.

The COVID-19 pandemic placed unprecedented pressures on maternity and neonatal services, disrupting models of care and amplifying existing stressors for healthcare staff. While much of the literature has focused on doctors and midwives, less is known about the emotional well-being of the broader multidisciplinary maternity and neonatal workforce, including neonatal nurses, sonographers, allied health, and administrative staff. Understanding the collective impact of workplace and personal factors on emotional well-being across this multidisciplinary group is essential for developing effective, inclusive workforce support strategies. A cross-sectional survey was conducted among maternity and neonatal staff, including doctors, midwives, nurses, sonographers, allied health, and administrative staff, from one tertiary and two secondary Australian hospitals. Survey responses were analysed using exploratory factor analysis to identify subscales representing key dimensions of emotional well-being, as well as workplace-related and personal factors influencing it. These subscales were then used in multiple hierarchical regression analyses to determine predictors of emotional well-being among staff. The strongest predictor of emotional well-being was the subscale 'Impact of COVID-19 on the Workplace' (β = -0.345, p < 0.001), encompassing factors such as perceived risk of contracting COVID-19, staff ability to perform duties, and adverse patient outcomes. Other significant predictors included average sleep duration (β = -0.230, p < 0.001), substance use (β = -0.210, p < 0.001), and time spent on outdoor activities (β = -0.130, p < 0.001). The predictive model explained 35.1% of the variance in emotional well-being (R² = 0.351). Workplace-related and personal factors significantly influenced maternity and neonatal staff well-being during the pandemic. Addressing workplace stress, promoting sleep, supporting healthy coping mechanisms, and encouraging restorative activities may improve staff well-being. These findings can inform the design of targeted workforce support programs and guide service planning strategies to strengthen resilience during future system shocks. Not applicable.

PMID 42928238
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多COVID-19 vaccine